These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9917572)

  • 1. ACE inhibitor therapy: benefits and underuse.
    Smith SC
    Am Fam Physician; 1999 Jan; 59(1):35-6, 38. PubMed ID: 9917572
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of ACE inhibitor therapy in treating cardiovascular disease.
    Flint L
    Nurs Times; 2004 Mar 23-29; 100(12):34-7. PubMed ID: 15067910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of ACE inhibitors and angiotensin receptor blockers in the treatment and prevention of chronic heart failure].
    Kárpáti P
    Orv Hetil; 2005 May; 146(18):827-31. PubMed ID: 15926627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
    MMW Fortschr Med; 2002 Oct; 144(40):49. PubMed ID: 12440300
    [No Abstract]   [Full Text] [Related]  

  • 8. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
    [No Abstract]   [Full Text] [Related]  

  • 9. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
    Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased QT dispersion with the D-allele of the ACE polymorphism.
    Woods DR; Brull D; Montgomery H
    Eur Heart J; 2001 Apr; 22(8):618-21. PubMed ID: 11286516
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.
    Pietrasik G; Goldenberg I; McNitt S; Polonsky B; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2009 Apr; 20(4):395-400. PubMed ID: 19017351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools].
    Modesti PA; Vanni S; Gensini GF
    Ital Heart J Suppl; 2003 Aug; 4(8):623-34. PubMed ID: 14655458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 15. Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade.
    Pitt B; Fonarow GC; Gheorghiade M; Deedwania PC; Duprez DA
    Am J Cardiol; 2006 May; 97(10A):26F-33F. PubMed ID: 16698332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction.
    Poole-Wilson PA
    Arch Mal Coeur Vaiss; 1994 Jun; 87 Spec No 2():35-8. PubMed ID: 7864720
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
    Gold JA; Rahko PS
    WMJ; 2004; 103(1):71-2. PubMed ID: 15101473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.